A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution.
BACKGROUND
Conventional lactate-buffered peritoneal dialysis (PD) fluids containing glucose and glucose degradation products are believed to contribute to the development of fibrosis and angiogenesis in the dialyzed peritoneum. To reduce potential negative effects of lactate, pyruvate was substituted as a buffer and its effects on peritoneal pathological alterations were studied in a chronic peritoneal exposure model in the rat.


METHODS
20 Wistar rats were infused intraperitoneally with pyruvate-buffered (n = 9) or lactate-buffered PD fluid. After 20 weeks of daily infusion, peritoneal function was assessed. In omental peritoneal tissue, the number of blood vessels was analyzed following alpha-smooth muscle actin staining. The degree of fibrosis was quantitated in Picro Sirius Red-stained sections and by assessment of the hydroxyproline content. Plasma lactate/pyruvate and betahydroxybutyrate/acetoacetate (BBA/AA) ratios were determined. Plasma and dialysate vascular endothelial growth factor (VEGF) levels were quantitated by ELISA.


RESULTS
The mass transfer area coefficient of creatinine was higher and the dialysate-to-plasma ratio of sodium was lower in pyruvate-treated animals compared to the lactate-treated group (0.11 vs 0.05 mL/min, p < 0.05, and 78% vs 89%, p < 0.05). The BBA/AA ratio tended to be lower in the pyruvate animals (p = 0.07). The number of blood vessels was lower in pyruvate-treated animals (16 vs 37 per field, p < 0.001). Total surface area, luminal area, and wall/total area of the vessels were larger in the pyruvate group. The degree of fibrosis was lower in intersegmental and perivascular areas of pyruvate-exposed animals. Effluent VEGF was higher in the pyruvate group.


CONCLUSIONS
Replacement of lactate by pyruvate resulted in changes in peritoneal solute transport, accompanied by a reduction in both peritoneal membrane angiogenesis and fibrosis, suggesting potentially novel mechanisms to reduce glucose-driven alterations to the peritoneal membrane in PD patients.
van Westrhenen
Roos
R
Division of Nephrology, Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Zweers
Machteld M
MM
Kunne
Cindy
C
de Waart
Dirk R
DR
van der Wal
Allard C
AC
Krediet
Raymond T
RT
D000818:Animals; D001692:Biological Transport; D005355:Fibrosis; D015312:Hemodialysis Solutions; D007150:Immunohistochemistry; D007773:Lactates; D008297:Male; D010530:Peritoneal Dialysis / Q000379:methods*; D010537:Peritoneum / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D011773:Pyruvates; D051381:Rats; D017208:Rats, Wistar; D014462:Ultrafiltration
D015312:Hemodialysis Solutions; D007773:Lactates; D011773:Pyruvates